羟基喜树碱与噻替哌灌注化疗对膀胱肿瘤术后临床预后的meta分析

李涛; 付生军; 杨立; 明星; 王志平

羟基喜树碱与噻替哌灌注化疗对膀胱肿瘤术后临床预后的meta分析

- 兰州大学第二医院泌尿外科, 兰州大学泌尿外科研究所, 甘肃省泌尿系统疾病临床医学中心, 甘肃省泌尿系统疾病研究重点实验室(兰州, 730030)

详细信息

通讯作者: 王志平,E-mail:erywzp@lzu.edu.cn

中图分类号: R737.14

收稿日期: 2013-01-24

Meta-analysis of hydroxy camptothecin versus thiotepa for intravesical perfusion after surgical procedure of bladder tumor

- Department of Urology, Institute of Urology, Key Laboratory of Diseases of Urological System Gansu Province, Gansu Nephro-Urological Clinical Center, Lanzhou University Second Hospital, Lanzhou, 730030, China

More Information

Corresponding author: WANG Zhiping, E-mail: erywzp@lzu.edu.cn

Received Date: 24 January 2013

摘要

摘要: 目的：评价膀胱肿瘤术后灌注羟基喜树碱（HCPT）和噻替哌（TT）对预防肿瘤复发的效果及其不良反应。方法：计算机检索Pubmed、Cochrane Library、CNKI、CBM、VIP及万方数据库，收集关于HCPT与TT膀胱灌注治疗肿瘤复发的随机对照实验（RCT），两名研究者根据纳入排除标准独立筛选文献，应用Revman 5.0 和Stata 11.0 进行数据处理。结果：通过筛选共纳入4个RCTs。meta分析结果提示，羟基喜树碱膀胱肿瘤术后灌注较噻替哌更能有效降低肿瘤复发风险（P=0.01）。2个研究报道了药物引起的不良反应，分析结果显示两者差异无统计学意义（P>0.05）。结论：膀胱肿瘤术后灌注羟基喜树碱较噻替哌更能有效降低肿瘤复发率，虽然有一定的不良反应，但都较轻微。
- 膀胱肿瘤 /
- 羟基喜树碱 /
- 噻替哌 /
- meta分析
Abstract: Objective: To evaluate the efficiency and side effects caused by intravesical perfusion of hydroxy camptothecin (HCPT) and thiotepa (TT) in preventing the recurrence of bladder cancer postoperatively.Method: Randomized controlled trials (RCTs) about intravesical perfusion of HCPT and TT for bladder tumor were retrieved on computer in Pubmed, Cochrane Library, CNKI, CBM, VIP and WanFang database. According to the inclusion and exclusion criteria, two researchers independently screened the trials, extracted the data, assessed the quality, finally conducted meta-analysis with Revman 5.0 and Stata 11.0 software.Result: A total of four RCTs were eligible. The results of meta-analysis showed that HCPT could more efficiently reduce the risk of recurrence of bladder tumor than TT (P=0.01). Two studies of the side effects caused by this treatments showed that there was no statistically difference (P>0.05).Conclusion: Intravesical perfusion of HCPT after surgical procedure can more effectively reduce the rate of recurrence of bladder tumor than TT and reveal less side effects.
- bladder tumor /
- hydroxy camptothecin /
- thiotepa /
- meta-analysis

HTML全文

参考文献(13)

[1]	Amit D, Hochberg A. Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences[J]. J Transl Med, 2010, 8:134.
[2]	Masood S, Sriprasad S, Palmer J H, et al. T1G3 bladder cancer——indications for early cystectomy[J]. Int Urol Nephrol, 2004, 36(1):41-44.
[3]	Pfost B, Seidl C, Autenrieth M, et al. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice[J]. J Nucl Med, 2009, 50(10):1700-1708.[ZK)]
[4]	Huncharek M, Geschwind J F, Witherspoon B, et al. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer:a meta-analysis of 3703 patients from 11 randomized trials[J]. J Clin Epidemiol, 2000, 53(7):676-680.
[5]	Weizer A Z, Tallman C, Montgomery J S. Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer[J]. World J Urol, 2011, 29(1):59-71.
[6]	Okamura T, Akita H, Ando R, et al. Single monthly bacillus Calmette-Guérin intravesical instillation is effective maintenance therapy to prevent recurrence in Japanese patients with non-muscle-invasive bladder cancer[J]. Int J Clin Oncol, 2012, 17(5):477-481.
[7]	程鸿鸣, 陈宗福, 李虹, 等. 羟基喜树碱灌注预防膀胱癌术后复发(附86例报告)[J]. 临床泌尿外科杂志, 2000, 15(2):62-63.
[8]	郝鹏, 秦迎春, 宋革. 膀胱肿瘤术后不同药物膀胱灌注的临床观察[J]. 黑龙江医药科学, 2005, 28(6):71-72.
[9]	杨嗣星, 王玲珑, 张孝斌, 等. 几种不同药物膀胱灌注预防膀胱肿瘤复发的疗效比较[J]. 湖北医科大学学报, 2000, 21(4):325-327.
[10]	应永强, 匡忠良, 王庆相, 等. 羟基喜树碱灌注预防膀胱癌复发的疗效观察[J]. 浙江肿瘤, 2000, 6(4):257.
[11]	Nakai Y, Nonomura N, Kawashima A, et al. Tumor multiplicity is an independent prognostic factor of non-muscle-invasive high-grade (T1G3) bladder cancer[J]. Jpn J Clin Oncol, 2010, 40(3):252-257.
[12]	McHugh L A, Grifiths T R. T1G3 transitional cell carcinoma of the bladder:recurrence, progression and survival[J]. BJU Int, 2004, 94(1):193.
[13]	Yao Y, Zhao H, Sun Y, et al. Combined chemotherapy of hydroxycampothecin with oxaliplatin as an adjuvant treatment for human colorectal cancer[J]. Tohoku J Exp Med, 2008, 215(3):267-278.